On May 13, 2020 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) reported the financial results and corporate updates for the first quarter 2020 (Press release, Evotec, MAY 13, 2020, View Source;announcements/press-releases/p/evotec-se-reports-first-quarter-2020-results-and-provides-corporate-update-5939 [SID1234557960]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
HIGHLIGHTS
STRONG PERFORMANCE IN BASE BUSINESS; INCREASED REVENUES DESPITE MODEST MILESTONE CONTRIBUTIONS IN Q1
15% increase in group revenues from contracts with customers to € 119.4 m (Q1 2019: € 103.8 m)
Strong revenue growth in both segments: EVT Execute revenues up 18% to € 118.2 m (Q1 2019: € 100.3 m), EVT Innovate revenues up 24% to € 23.3 m (Q1 2019: € 18.8 m)
Stable adjusted Group EBITDA of € 30.0 m (Q1 2019: € 30.0 m); adjusted EBITDA of € 35.4 m for EVT Execute (Q1 2019: € 32.2 m)
Increased commitment into unpartnered R&D with expenses of € 11.4 m (Q1 2019: € 8.1 m)
Continued strong strategic liquidity position of € 320.7 m (31 December 2019: € 320.0 m)
No material impact by COVID-19 pandemic on financial development so far
EVT EXECUTE & EVT INNOVATE – STRONG PERFORMANCE AND STRATEGIC POSITION IN BOTH BUSINESS SEGMENTS
Important step into gene therapy with Evotec GT and multi-year gene therapy research alliance with Takeda
New and extended drug discovery and development agreements in EVT Execute (e.g. Amgen, Ildong)
Just – Evotec Biologics on track for success: Strengthened position through first strategic J.POD partnership with MSD and continued good construction progress of the first J.POD facility in Seattle
Advancement of an additional endometriosis programme into clinical Phase I within Bayer alliance, triggering a € 2 m milestone payment
Strengthening of Evotec’s iPSC-based cell therapy platform EVOcells through licensing agreement with panCELLa
Regaining global rights on iPSC-based beta cell replacement therapy from Sanofi and initiation of EVT Innovate initiative QRbeta Therapeutics (after period-end)
Strategic equity investment and partnership with leon-nanodrugs expands formulation platform
Evotec contributing to selected global initiatives to fight Tuberculosis and COVID-19
GUIDANCE FOR FULL-YEAR 2020 CONFIRMED
Unchanged business outlook, taking into account currently visible negative COVID-19 effects
Total group revenues expected to range from € 440 – 480 m (2019: € 446.4 m)
Adjusted Group EBITDA expected to be in the range of € 100 – 120 m (2019: € 123.1 m)
Unpartnered Group R&D expenses of approx. € 40 m
More detailed information and financial tables are available in our Quarterly Statement Q1 published on the Evotec website under the following link: View Source
Webcast/Conference Call
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance in the reporting period. Furthermore, the Management Board will present an outlook for fiscal year 2020. The conference call will be held in English.
Conference call details
Date: Thursday, 14 May 2020
Time: 02.00 pm CEST (08.00 am EDT, 01.00 pm BST)
A simultaneous slide presentation for participants dialling in via phone is available at View Source
Webcast details
To join the audio webcast and to access the presentation slides you will find a link on our home page shortly before the event.
A replay of the conference call will be available for seven days after the conference and can be accessed in Europe by dialling +49 69 20 17 44 221 (Germany) or +44 20 3364 5150 (UK) and in the USA by dialling +1 844 307 9362. The access code is 315586222#. The on-demand version of the webcast will be available on our website under View Source